{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"16","value":"2"}]}],"title":"cGVHD overall: Day 180"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7","upperLimit":"31","value":"15"}]}],"title":"cGVHD overall: Day 365"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7","upperLimit":"31","value":"15"}]}],"title":"cGVHD overall: Day 1095"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"16","value":"2"}]}],"title":"cGVHD Moderate / Severe: Day 180"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4","upperLimit":"25","value":"10"}]}],"title":"cGVHD Moderate / Severe: Day 365"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4","upperLimit":"25","value":"10"}]}],"title":"cGVHD Moderate / Severe: Day 1095"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"16","value":"2"}]}],"title":"cGVHD Requiring Systemic Therapy: Day 180"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"22","value":"7"}]}],"title":"cGVHD Requiring Systemic Therapy: Day 365"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"22","value":"7"}]}],"title":"cGVHD Requiring Systemic Therapy: Day 1095"}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"The cumulative incidence of chronic Graft Versus Host Disease (GVHD). Subjects who receive all 4 doses of carfilzomib at the maximum tolerated dose level will be considered evaluable for endpoint analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered 20 mg/m\\^2 on days 1 and 2; 36 mg/m\\^2 of Carfilzomib on days 6 and 7.","id":"OG000","title":"Dose Level 3 - Maximum Dose Carfilzomib 36 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Subjects who received all 4 doses of carfilzomib at the maximum tolerated dose (MTD) level (dose level 3, 36 mg/m\\^2): 39 subjects total. Note: three subjects who completed 4 doses of carfilzomib at the MTD during the phase 1 portion of the study were included in phase 2 analysis.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Phase II: Cumulative Incidence of Chronic GVHD","type":"SECONDARY","unitOfMeasure":"percentage of participants"}